Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4383 studies found for:    "Antineoplastic Agents, Alkylating"
Show Display Options
Rank Status Study
1 Recruiting Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma;   Follicular Lymphoma, Grade 3b;   Transformed Lymphoma / DLBCL
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
2 Recruiting PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
Conditions: Primary Myelofibrosis;   Myeloproliferative Disorders
Interventions: Procedure: Allogeneic hematopoietic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Drug: Ruxolitinib
3 Recruiting GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Conditions: Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia;   Mixed-Lineage Acute Leukemias
Interventions: Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Bendamustine
4 Recruiting Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Conditions: Leukemia, Chronic Myeloid;   Myelodysplastic Syndromes;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Interventions: Procedure: Unrelated allogeneic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Thymoglobulin
5 Active, not recruiting Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Immune System Diseases
Interventions: Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Procedure: Allogeneic hematopoietic stem cell transplantation
6 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
7 Terminated
Has Results
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: SGN-30
8 Completed A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Conditions: Ovarian Neoplasms;   Endocrine Gland Neoplasms;   Neoplasms by Site;   Neoplasms;   Ovarian Diseases;   Adnexal Diseases;   Genital Diseases, Female
Interventions: Drug: Trabectedin;   Drug: Dexamethasone
9 Completed A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
Condition: HIV Infections
Interventions: Drug: Nelfinavir mesylate;   Drug: Lamivudine;   Drug: Filgrastim;   Drug: Stavudine;   Drug: Cyclophosphamide
10 Completed A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
Conditions: Breast Neoplasms;   Neoplasms;   Neoplasms by Site;   Breast Diseases;   Skin Diseases
Intervention: Drug: ET743
11 Not yet recruiting Disulfiram in Recurrent Glioblastoma
Conditions: Glioma;   Glioblastoma
Interventions: Drug: Disulfiram;   Dietary Supplement: Copper;   Drug: Alkylating Agents
12 Not yet recruiting Aprepitant Versus Olanzapine With High Dose Melphalan
Conditions: Nausea;   Vomiting
Interventions: Drug: Aprepitant;   Drug: Olanzapine
13 Recruiting ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors
Condition: Lymphoblastic Lymphoma
Interventions: Drug: Rabbit Anti-human Thymoglobulin (r-ATG);   Drug: Placebo
14 Recruiting Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Biological: Anti-PD-L1 CSR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
15 Not yet recruiting Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
Condition: Acute Myeloid Leukemia
Interventions: Drug: Idarubicin;   Drug: Cytarabine;   Drug: Cyclophosphamide;   Drug: Physician-Directed Regimens without Cyclophosphamide
16 Not yet recruiting Iguratimod as Treatment for Diffused Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: Iguratimod;   Drug: Cyclophosphamide;   Drug: Azathioprine
17 Recruiting Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
Condition: Primary CNS Lymphoma
Interventions: Drug: methotrexate;   Drug: temozolomide
18 Not yet recruiting CD19-redirected Autologous Cells (CAR-CD19 T Cells)
Condition: CD19 Positive Malignant B-cell Leukemia and Lymphoma
Interventions: Genetic: CAR-CD19 T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
19 Not yet recruiting Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
Condition: Solid Tumors
Interventions: Genetic: GAP T cells;   Drug: Cytoxan;   Drug: Fludara
20 Not yet recruiting Trabectedin Maintenance Post 1st-line in STS
Condition: Sarcoma, Soft Tissue
Intervention: Drug: Trabectedin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years